Lion Point Capital’s Innate Pharma IPHA Stock Holding History

Lion Point Capital’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$149K	Hold	81,151	–	–	0.71%	33
2026 Q1	$104K	Hold	81,151	–	–	0.62%	34
2025 Q4	$142K	Buy	+81,151	New	+$157K	0.73%	35

Other funds holding IPHA

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SmartHarvest Portfolios Poulsbo, Washington $309M AUM

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Lion Point Capital's IPHA Position: Q2 2026 in Review

Lion Point Capital held its Innate Pharma (IPHA) position steady in Q2 2026 at 81,151 shares worth $149K. The position accounts for 0.71% of the portfolio, ranked #33.

Lion Point Capital first reported a position in IPHA in Q4 2025 and has held it in 3 quarters since. 10 funds tracked by Wall St. Rank hold IPHA as of Q2 2026.

Lion Point Capital held 81,151 shares of Innate Pharma worth $149K as of Q2 2026.
Lion Point Capital left its Innate Pharma share count unchanged in Q2 2026.
Innate Pharma made up 0.71% of Lion Point Capital's portfolio in Q2 2026, its #33 holding.
Lion Point Capital first reported a position in Innate Pharma in Q4 2025 and has held it in 3 quarters since.
10 funds tracked by Wall St. Rank held Innate Pharma as of Q2 2026.

Based on Lion Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.